BioMarin makes treatments for rare genetic diseases.
BioMarin Pharmaceutical Inc. (BMRN) is expected to report earnings on Monday, October 26, 2026, after the close. Estimated release time 16:07 ET. Consensus EPS estimate is $1.37.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | FY2026 Q2 | $0.95 | $1.20 | +26.7% | $989.71M |
| 2026-05-05 | FY2026 Q1 | $0.78 | $0.55 | -29.5% | $766.21M |
| 2026-02-23 | FY2025 Q4 | $0.17 | $-0.24 | -241.7% | $874.57M |
| 2025-10-28 | FY2025 Q3 | $-0.15 | $-0.16 | -6.7% | $776.13M |
| 2025-08-05 | FY2025 Q2 | $0.86 | $1.25 | +45.2% | $825.41M |
| 2025-05-02 | FY2025 Q1 | $0.71 | $0.97 | +35.9% | $745.14M |
| 2025-02-19 | FY2024 Q4 | $0.54 | $0.66 | +22.2% | $747.31M |
| 2024-10-29 | FY2024 Q3 | $0.53 | $0.57 | +7.3% | $745.74M |
BMRN has beaten consensus EPS in 5 of its last 8 reported quarters.
Highlights from BMRN's Aug 6 report: EPS of $1.20 — a big beat vs the $0.95 estimate (+27%); revenue of $990M — a beat vs the $932M consensus (+6%). Focus now shifts to Voxzogo growth and pipeline focus.
See BMRN on the live calendar →